Drug research and development and unmet needs for advanced-stage hepatocellular carcinoma
10.3760/cma.j.cn501113-20240301-00101
- VernacularTitle:晚期肝细胞癌药物研发与未满足的需求
- Author:
Huabang ZHOU
1
;
Heping HU
Author Information
1. 海军军医大学附属东方肝胆外科医院肝胆内科，上海 200438
- Keywords:
Primary liver cancer;
Hepatocellular carcinoma;
Targeting drug;
Immunotherapy
- From:
Chinese Journal of Hepatology
2024;32(4):306-311
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and is a global health challenge. Radical surgical resection is the most effective method to achieve long-term survival for HCC. Regrettably, the vast majority of HCC patients lose the opportunity for radical resection at the time of diagnosis due to advanced tumors or poor liver reserve capacity. HCC is resistant to conventional chemotherapy, and in the past, there have been no definite and effective systemic therapeutic drugs. Fortunately, over the last decade, the research and development of molecular targeted therapy and immunotherapy drugs for HCC have made rapid progress, and a variety of drugs and combination therapy regimens have been successively approved for clinical use. However, the overall therapeutic effect is still not ideal and needs further improvement.
